Pharmalot

Pharmalot

Pharmalittle: Pelosi unveils aggressive drug pricing plan; Novartis says baby death not related to gene therapy

By Ed Silverman

Pharmalot

Flawed trials supported half of recent approvals of cancer drugs in Europe, study says

By Ed Silverman

Pharmalot

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

By Ed Silverman

Pharmalot

Pharmalittle: Senators ask FTC to probe pharma mergers; is the Purdue settlement blood money?

By Ed Silverman

Pharmalot

Lawmakers ask FTC to scrutinize pharma mergers over antitrust concerns

By Ed Silverman

Pharmalot

Medicare Part D rebates ‘substantially’ reduced drug spending, but not enough to offset price hikes

By Ed Silverman

Pharmalot

Pharmacy head who researched Zantac link to carcinogen says FDA has ‘downplayed the problem’

By Ed Silverman

Pharmalot

Pharmalitttle: Purdue looks to extend bankruptcy shield to Sacklers; AARP runs feisty campaign on drug prices

By Ed Silverman

Pharmalot

Wholesale drug prices have been falling, and so have net prices

By Ed Silverman

Pharmalot

Pharmalittle: Purdue bankruptcy sets tone for opioid cases; Sanders criticizes Biden for praising pharma

By Ed Silverman

Pharmalot

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Opioid settlements may yield tax breaks for drug makers; EMA probes heartburn meds for carcinogens

By Ed Silverman

Pharmalot

Consumer groups and unions urge FTC to block AbbVie and Allergan merger

By Ed Silverman

Pharmalot

Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews

By Ed Silverman

Pharmalot

Vertex strikes a deal with Scotland for its cystic fibrosis medicines, but will England be next?

By Ed Silverman

Pharmalot

Pharmalittle: Merck downplayed Propecia side effect data; Purdue reaches tentative deal in opioid cases

By Ed Silverman

Pharmalot

FDA rebukes Sprout over a statement claiming warning on its female libido pill was removed

By Ed Silverman

Pharmalot

Pharmalittle: Lilly hid secret payments to sway a verdict; attorneys general got money from opioid makers

By Ed Silverman

Pharmalot

FDA is inspecting more foreign plants, but fewer domestic facilities

By Ed Silverman

Pharmalot

Pharmalittle: Pelosi’s drug pricing plan veers left; Purdue must face public nuisance claims in opioid case

By Ed Silverman

Pharmalot

FDA rejects bid for a moratorium on opioid approvals as scrutiny of the agency heats up

By Ed Silverman

Pharmalot

Reeling from scandal, Novartis vows to voluntarily release info on manipulated data in the future

By Ed Silverman

Pharmalot

Pharmalittle: Purdue says talks to settle opioid suits continue; pharma sues to block Canadian pricing regs

By Ed Silverman

Pharmalot

Judge dismisses real estate tycoon’s lawsuit against his son

By Jonathan Saltzman — Boston Globe

Sun Pharma shipped medicines into Alabama for two years without a permit

Generic makers claim Medicare Part D plans crowd them out, hurting seniors

Up and down the ladder: The latest comings and goings

Pharmalittle: McConnell says House drug bill is dead on arrival; Purdue wants to pay bonuses

Pharmalittle: Pelosi unveils aggressive drug pricing plan; Novartis says baby death not related to gene therapy

Flawed trials supported half of recent approvals of cancer drugs in Europe, study says

Sandoz halts global distribution of heartburn med over carcinogen link while Canada tells other manufacturers to stop

Pharmalittle: Senators ask FTC to probe pharma mergers; is the Purdue settlement blood money?

Lawmakers ask FTC to scrutinize pharma mergers over antitrust concerns

Medicare Part D rebates ‘substantially’ reduced drug spending, but not enough to offset price hikes

Pharmacy head who researched Zantac link to carcinogen says FDA has ‘downplayed the problem’

Pharmalitttle: Purdue looks to extend bankruptcy shield to Sacklers; AARP runs feisty campaign on drug prices

Wholesale drug prices have been falling, and so have net prices

Pharmalittle: Purdue bankruptcy sets tone for opioid cases; Sanders criticizes Biden for praising pharma

FDA and EMA are now probing carcinogen in Zantac and other heartburn meds

Up and down the ladder: The latest comings and goings

Pharmalittle: Opioid settlements may yield tax breaks for drug makers; EMA probes heartburn meds for carcinogens

Consumer groups and unions urge FTC to block AbbVie and Allergan merger

Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews

Vertex strikes a deal with Scotland for its cystic fibrosis medicines, but will England be next?

Pharmalittle: Merck downplayed Propecia side effect data; Purdue reaches tentative deal in opioid cases

FDA rebukes Sprout over a statement claiming warning on its female libido pill was removed

Pharmalittle: Lilly hid secret payments to sway a verdict; attorneys general got money from opioid makers

FDA is inspecting more foreign plants, but fewer domestic facilities

Pharmalittle: Pelosi’s drug pricing plan veers left; Purdue must face public nuisance claims in opioid case

FDA rejects bid for a moratorium on opioid approvals as scrutiny of the agency heats up

Reeling from scandal, Novartis vows to voluntarily release info on manipulated data in the future

Pharmalittle: Purdue says talks to settle opioid suits continue; pharma sues to block Canadian pricing regs

Judge dismisses real estate tycoon’s lawsuit against his son